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Previous studies have reported that risk of cardiovascular morbidity and mortality
substantially increases in hypertensive patients, especially among those with inadequate
blood pressure control. Two common antihypertensive drug classes including thiazide
diuretics and angiotensin-converting enzyme (ACE) inhibitors affect different enzymes
in the renin-angiotensin-aldosterone system (RAAS). In the RAAS, angiotensinogen is
converted into angiotensin II which increases blood pressure through vasoconstriction.
Using a case-only design with 3448 high-risk hypertensive individuals from the Genetics of
Hypertension Associated Treatment (GenHAT) study, we examined whether seven single
nucleotide polymorphisms (SNPs) in the angiotensinogen gene (AGT ) interact with three
classes of antihypertensive drugs including chlorthalidone (a thiazide diuretic), lisinopril
(an ACE inhibitor), and amlodipine (a calcium channel blocker) to modify the risk of
incident coronary heart disease (CHD) and heart failure (HF) among Caucasian and African
American participants, separately. We found no gene by treatment interactions to be
statistically significant after correction for multiple testing. However, some suggestive
results were found. African American participants with the minor allele of rs11122576 had
over two-fold higher risk of CHD when using chlorthalidone compared to using amlodipine,
or lisinopril compared to amlodipine (p = 0.006 and p = 0.01, respectively). Other marginal
associations are also reported among both race groups. The findings reported here
suggest that rs11122576 could contribute to future personalization of antihypertensive
treatment among African Americans though more studies are needed.
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INTRODUCTION
Hypertension is one of the most common conditions in the U.S.
affecting about 76.4 million (about 1 out of 3) adults in 2012,
and is a large contributor to heart disease and stroke incidence
and mortality. Notably, less than half of all hypertensive patients
have adequate blood pressure control. In 2008, the overall death
rate associated with hypertension was 18.3% (Roger et al., 2012).
Additionally, treating hypertension costs the U.S. economy $131
billion annually for direct medical expenses, and another $25
billion indirectly due to the loss of productivity (Heidenreich
et al., 2011). Antihypertensive pharmacogenetic research has the
potential to discover genetic contributors to variability in antihy-
pertensive response, and tailoring therapy based on an individ-
ual’s genetic make-up has the potential to mitigate cardiovascular
disease (CVD) outcomes among treated hypertensives.
The renin-angiotensin-aldosterone system (RAAS) plays a
major role in maintaining salt-water balance and controlling
blood pressure (Li et al., 2013). Multiple studies have reported
genes belonging to this pathway are associated with hyperten-
sion and its sequelae (Jeunemaitre et al., 1992; Mahmood et al.,
2003; Pasquale et al., 2005; Al-Najai et al., 2013; Li et al., 2013).
Additionally, many antihypertensive drugs act to downregulate
this pathway. Therefore, genes belonging to the RAASmaymodify
antihypertensive treatment response and risk for adverse out-
comes (Figure 1). Angiotensinogen is an upstream member of
the RAAS encoded by the AGT gene on chromosome 1. It is
primarily synthesized in the liver and then cleaved by renin
from the kidney to form angiotensin I. Angiotensin I is further
cleaved by the angiotensin-converting enzyme (ACE) to form
the biologically active form called angiotensin II. In the kidney,
angiotensin II induces vessel contraction via the AT1 receptor and
Na+ reabsorption in epithelial cells at the proximal tubules via
aldosterone release (Craig and Stitzel, 2003). Among the three
most widely used antihypertensive drug classes (diuretics, ACE
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inhibitors, and calcium channel blockers), ACE inhibitors directly
affect the RAAS through blocking the conversion of angiotensin
I to angiotensin II. Thiazide diuretics can acutely activate RAAS
through the inhibition of Na+ reabsorption and reduction of
plasma volume (Sica, 2004; Duarte and Cooper-DeHoff, 2010).
Polymorphisms in the AGT gene have been found to be asso-
ciated with CVD, especially coronary heart disease (CHD), and
heart failure (HF) (Chen et al., 2012; Li et al., 2013). Therefore, we
hypothesize that CHD and HF risk among hypertensive patients
treated with these drugsmay bemodified by variations in theAGT
gene. Polymorphisms in the AGT genemay affect this risk directly
or through downstream effects on other members of the RAAS
pathway.
In the current study, we evaluated whether seven SNPs in the
AGT gene affect risk of CHD and HF in high-risk hypertensive
individuals randomized to one of three classes of antihyperten-
sive treatment as part of the Genetics of Hypertension Associated
Treatment Study (GenHAT) using a case-only design (Arnett
et al., 2002).
MATERIALS AND METHODS
STUDY POPULATION
The GenHAT study (N = 39,114) was initiated to evaluate if
several genes associated with hypertension modify the risk of
CHD and other CVD outcomes in patients taking different
anti-hypertensive drug classes (Arnett et al., 2002). GenHAT is
an ancillary study of the Antihypertensive and Lipid Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT), a random-
ized, double blind, multicenter clinical trial with 42,418 high-risk
hypertensive persons 55 years of age or older. Participants were
randomized into four groups defined by the class of antihyperten-
sive medication they were assigned to, including chlorthalidone,
lisinopril, amlodipine, and doxazosin (an α-adrenergic blocker),
in a ratio of 1.7:1:1:1, respectively. Due to the early discontinua-
tion of the doxazosin arm owing to a significant (25%) increase
in the incidence of CVD compared to the chlorthalidone arm, we
have not included the doxazosin arm in these analyses (ALLHAT
FIGURE 1 | Renin-Angiotensin pathway and the roles of ACE
inhibitors, diuretics.
Collaborative Research Group, 2000). Participants randomized
to chlorthalidone, lisinopril, or amlodipine were followed for an
average of 4.9 years. For more details regarding study design and
methodology related to GenHAT and ALLHAT, see Arnett et al.
(2002) and Davis et al. (1996). In the case-only phase of GenHAT,
9336 participants from three treatment groups affected by fatal
CHD, non-fatal myocardial infarction (MI), stroke, HF, coro-
nary revascularization, angina, peripheral arterial disease, end-
stage renal disease, or all-cause death, were genotyped for vari-
ants in several hypertension-associated genes, including the AGT
gene.
The results presented here focus on two outcomes, namely,
CHD and HF. The primary outcome for both ALLHAT and
GenHAT was CHD, defined as fatal CHD or non-fatal MI
(N = 2253). The secondary outcome for this study included
HF (treated, fatal, or hospitalized) (N = 1728). Outcomes were
reported by the clinical investigators and validated through the
review of death certificates and hospitalization records. For a
more detailed description of ALLHAT outcomes, see Davis et al.
(1996).
This research was approved by the institutional review boards
at the University of Alabama at Birmingham, the University of
Texas Health Science Center, and the University of Minnesota.
Informed consent was collected from all participants in ALLHAT.
GENOTYPING METHODS
The DNA of participants from GenHAT was extracted from
stored blood using Gentra Purgene Kits (Minneapolis, MN)
and 600 loci that were potential candidates for blood pres-
sure regulation or CVD were genotyped by Illumina (San
Diego, CA, USA) technology. The amplification success rate
was 97%, and the reproducibility was found to be 99.99%.
Tag SNPs were selected using the Haploview Program (http://
www.broad.mit.edu/mpg/haploview/) and based on two ethnic
sources: the Caucasian (CEU) and Yoruban (YRI) population
from the International HapMap project (http://www.hapmap.
org/). The 10 AGT polymorphisms genotyped in GenHAT
were rs7079, rs5051, rs5041, rs3789678, rs34829218, rs2493133,
rs2493129, rs2478544, rs11568032, rs11122576. Three AGT poly-
morphisms (rs5041, rs34829218, rs11568032) with minor allele
frequency<5% were not included in the analyses presented.
FIGURE 2 | AGT gene structure and SNPs locations. TSS, transcriptional
start site. The first bases in the brackets are the common alleles.
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STATISTICAL METHODS
To test for baseline differences between treatment groups, we used
ANOVA for continuous variables and chi-square tests or Fisher’s
exact test (i.e., for any cell size < 10 observations) for categori-
cal variables. Principal component analysis (PCA) of 64 ancestry
informative markers (AIMs) was used to inform genetically deter-
mined Caucasian and African American race (Lynch et al., 2012).
Each of the seven AGT SNPs was tested for Hardy Weinberg
Equilibrium (HWE) stratified by genetically defined race, which
will be referred to as race from here on for simplicity. The linkage
disequilibrium (LD) between the seven AGT SNPs was analyzed
using HAPLOVIEW (Figure 2) (Copyright ©2003–2006 Broad
Institute of MIT and Harvard). Logistic regression was used to
test for gene-by-treatment effects among the case groups, with
treatment group modeled as the dependent variable and geno-
type as the independent variable. Three separate comparisons
(chlorthalidone vs. amlodipine, chlorthalidone vs. lisinopril, and
lisinopril vs. amlodipine) were conducted to test the interaction
of genes and treatments. The additive genetic model was tested
where the common allele homozygote was treated as the reference
group. The dominant genetic model was used for SNPs which
have any cell size less than 10 observations. A p-value of 0.05 was
considered as suggestive evidence for an association. A Bonferroni
correction was used to adjust for multiple testing within each
outcome and race: specifically, we considered six independent
SNPs (rs5051 and rs2493133 were determined to be in strong LD,
described below) and three treatment comparisons; therefore, α
was adjusted to 0.05/18 = 0.003. SAS version 9.3 (SAS Institute
Inc., Cary, NC, USA) was used for all analyses. Using Quanto V.
1.2 software (Gauderman and Morrison, 2009) for the case-only
design with allele frequency is 0.05 or greater, and type 1 error
rate set to 0.003, we have 81% power to detect an interaction odds
ratio of 1.80 or greater for Caucasians and 80% power to detect
an interaction odds ratio of 2.2 or greater for African-Americans.
RESULTS
Table 1 shows the baseline characteristics of 3448 subjects
included in this analysis. There were no significant differences
in the baseline characteristics between three medication arms.
Table 2 presents allele frequencies for the seven AGT variants by
ethnic subgroups. The allelic frequency of the seven AGT variants
was not significantly different between three medication arms in
either race group except for rs2493129 among Caucasians. The
minor allele frequencies for rs5051 and rs2493331 differed con-
siderably between African Americans and Caucasians, but minor
allele frequencies were comparable in both races for all other
SNPs.
Many of the variants were not in HWE in the either race group,
possibly due to the case-only design as alleles contributing to
“case” status may not be random. In the Caucasian group, rs7079
(p = 0.14) and rs2478544 (p = 0.09) were in HWE but five SNPs
were not (rs5051, rs3789678, rs2493133, rs2493129, rs11122576,
p < 0.05). For the African-American group, five SNPs were in
HWE (p > 0.05) but rs7079 (p = 0.006) and rs3789678 (p =
0.003) were not.
Figure 2 shows the location of the seven SNPs in the
AGT gene considered in this study. Five of the seven poly-
morphisms (rs3789678, rs11122576, rs2493133, rs2478544,
Table 1 | Baseline characteristics for case-only participants (n = 3448)
by treatment group, mean (SD) unless otherwise noted.
Characteristics Chlorthalidone Amlodipine Lisinopril P-value
Sample size (n, %) 1511 (43.8) 1004 (29.1) 933 (27.1)
Age, mean 69.6 (8.1) 69.1 (8.0) 69.8 (8.1) 0.13
Caucasiansa, n (col%) 1000 (60.6) 649 (58.5) 597 (58.5) 0.93
African Americana, n
(col%)
511 (31.0) 355 (32.0) 336 (32.9)
Women, n (col %) 605 (40.0) 403 (40.1) 375 (40.2) 0.99
Previous
antihypertensive
treatment, n (col%)
1385 (91.7) 942 (93.8) 862 (92.4) 0.13
Baseline SBP in mmHg,
mean (SD)
147.4 (16.2) 146.9 (16.5) 147.9 (16.1) 0.40
Baseline DBP in
mmHg, mean (SD)
82.4 (10.3) 82.0 (10.5) 82.2 (11.0) 0.70
ELIGIBILITY RISK FACTORS
Current cigarette
smoker, n (col %)
319 (21.1) 202 (20.1) 210 (22.5) 0.66
History of MI or stroke,
n (%)
563 (37.3) 350 (34.9) 323 (34.6) 0.31
History of CABG, n (%) 344 (22.8) 211 (21.0) 215 (23.0) 0.49
Other atherosclerotic
CVD, n (%)
449 (29.7) 313 (31.2) 271 (29.1) 0.57
Major ST
depression/T-wave
inversion, n (%)
177 (11.8) 135 (13.5) 104 (11.2) 0.25
Type 2 diabetes, n (%) 654 (43.3) 444 (44.2) 400 (42.9) 0.82
HDL-C <35 mg/dL,
n (%)
191 (12.6) 108 (10.8) 92 (9.9) 0.09
LVH by
electrocardiogram,
n (%)
256 (16.9) 177 (17.6) 172 (18.4) 0.64
Body mass index,
mean (SD), kg/m2
29.9 (6.6) 30.2 (6.6) 29.6 (6.4) 0.11
Current Aspirin use,
n (%)
668 (44.2) 443 (44.1) 424 (45.4) 0.67
Current Estrogen
supplementation,n (%)
82 (13.6) 61 (15.1) 42 (11.2) 0.35
Fasting glucose, mg/dL 132.9 (63.8) 130.4 (63.5) 127.7 (60.8) 0.23
Creatinine, mg/dL 1.1 (0.4) 1.1 (0.3) 1.1 (0.3) 0.62
Total cholesterol, mg/dL 218.2 (46.8) 216.9 (44.9) 216.5 (44.0) 0.64
HDL cholesterol, mg/dL 44.5 (14.7) 45.5 (14.5) 44.9 (14.1) 0.24
LDL cholesterol, mg/dL 138.3 (37.3) 136.9 (39.1) 138.3 (38.4) 0.64
Fasting triglycerides,
mg/dL
188.1 (164.5) 178.6 (144.9) 177.9 (137.5) 0.25
Potassium, mmol/L 4.4 (0.5) 4.3 (0.5) 4.3 (0.5) 0.74
SBP, systolic blood pressure; DBP, diastolic blood pressure; MI, myocardial
infraction; CABG, coronary artery bypass grafting; CVD, cardiovascular disease;
CHD, coronary heart disease; HDL-C, HDL cholesterol; LVH, left ventricular
hypertrophy.
Test of differences between genotype groups: ANOVA for continuous variables,
chi-square for categorical variables.
aRace is genetically determined.
rs2493129) were intronic and two (rs5051, rs7079) were in
untranslated regions. Two SNPs were in tight LD (i.e., rs5051 and
rs2493133) in both race groups, as calculated using HAPLOVIEW
(Figure 3). The correlation coefficients for rs5051-rs2493133
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Table 2A | Alleles frequency of 7 AGT variants and p-values
corresponding to the test of allele frequencies differences among
treatments for case-only participants among Caucasians (n = 2246).
AGT variants Chlorthalidone Amlodipine Lisinopril P-value
rs7079 CC 437 (45.5%) 297 (47.7%) 252 (44.8%) 0.33
AC 402 (41.9%) 258 (41.4%) 255 (45.4%)
AA 121 (12.6%) 68 (10.9%) 55 (9.8%)
rs5051 TT 193 (19.8%) 120 (19.1%) 108 (18.7%) 0.22
TC 435 (44.5%) 316 (50.2%) 270 (46.6%)
CC 349 (35.7%) 194 (30.8%) 201 (34.7%)
rs3789678 CC 779 (79.3%) 494 (77.8%) 462 (79.5%) 0.89
TC 188 (19.1%) 132 (20.8%) 109 (18.8%)
TT 16 (1.6%) 9 (1.4%) 10 (1.7%)
rs2493133 CC 194 (20.2%) 117 (18.7%) 106 (18.5%) 0.24
TC 423 (43.9%) 311 (49.7%) 268 (46.8%)
TT 346 (35.9%) 198 (31.6%) 199 (34.7%)
rs2493129 GG 941 (95.1%) 587 (91.7%) 551 (93.1%) 0.01
AG 46 (4.7%) 53 (8.3%) 40 (6.8%)
AA 3 (0.3%) 0 (0%) 1 (0.2%)
rs2478544 GG 642 (68.4%) 396 (65.7%) 386 (68.7%) 0.36
GC 263 (28%) 191 (31.7%) 154 (27.4%)
CC 34 (3.6%) 16 (2.7%) 22 (3.9%)
rs11122576 AA 863 (87.6%) 543 (84.5%) 493 (83.3%) 0.07
AG 112 (11.4%) 96 (14.9%) 91 (15.4%)
GG 10 (1%) 4 (0.6%) 8 (1.4%)
Test of differences between genotype groups: chi-square and Fisher’s exact
tests. Fisher’s exact test was used for SNP which has any cell size less than
10 observations in frequency table.
were similar in Caucasians (r2 = 0.919) and African-Americans
(r2 = 0.761).
The race-specific analysis includes 1500 and 1094 cases of
CHD and HF, respectively, for the Caucasian group, and 753
and 634 cases of CHD and HF, respectively, for the African-
Americans. Tables 3A,B demonstrate the results of the gene
by treatment interaction analyses for the seven AGT SNPs.
Overall there was little consistency by race. Among African-
Americans, those with the minor allele (A) of rs7079 were 90%
more likely to have CHD when using chlorthalidone compared
to those using amlodipine (p = 0.01). Additionally, African-
American participants with the minor allele (G) of rs11122576
were over two times as likely to have CHD when using chlorthali-
done compared to amlodipine (OR = 2.5, p = 0.006) and
using lisinopril compared to amlodipine (OR = 2.6, p = 0.01).
Among Caucasian participants, those with the minor allele
(G) of rs11122576 were 40% less likely to have CHD when
using chlorthalidone compared to using amlodipine (OR =
0.6, p = 0.01), and were 30% less likely to have CHD when
using chlorthalidone compared to using lisinopril (OR = 0.7,
p = 0.03).
Table 2B | Alleles frequency of 7 AGT variants and p-values
corresponding to the test of allele frequencies differences among
treatments for case-only participants among African Americans
(n = 1202).
AGT variants Chlorthalidone Amlodipine Lisinopril P-value
rs7079 CC 401 (80%) 296 (85.6%) 281 (85.2%) 0.11
AC 91 (18.2%) 47 (13.6%) 42 (12.7%)
AA 9 (1.8%) 3 (0.9%) 7 (2.1%)
rs5051 TT 353 (70.5%) 258 (73.7%) 244 (73.7%) 0.11
TC 128 (25.6%) 88 (25.1%) 76 (23%)
CC 20 (4%) 4 (1.1%) 11 (3.3%)
rs3789678 CC 316 (62.8%) 221 (64.4%) 196 (59.2%) 0.43
TC 153 (30.4%) 106 (30.9%) 116 (35.1%)
TT 34 (6.8%) 16 (4.7%) 19 (5.7%)
rs2493133 CC 319 (64.2%) 229 (67.6%) 222 (68.3%) 0.11
TC 155 (31.2%) 103 (30.4%) 86 (26.5%)
TT 23 (4.6%) 7 (2.1%) 17 (5.2%)
rs2493129 GG 437 (86.2%) 296 (84.8%) 277 (83.4%) 0.83
AG 67 (13.2%) 51 (14.6%) 52 (15.7%)
AA 3 (0.6%) 2 (0.6%) 3 (0.9%)
rs2478544 GG 150 (31.9%) 88 (27.2%) 107 (34.6%) 0.26
GC 222 (47.2%) 170 (52.5%) 137 (44.3%)
CC 98 (20.9%) 66 (20.4%) 65 (21%)
rs11122576 AA 452 (89.2%) 328 (94%) 295 (88.3%) 0.05
AG 52 (10.3%) 19 (5.4%) 37 (11.1%)
GG 3 (0.6%) 2 (0.6%) 2 (0.6%)
Test of differences between genotype groups: chi-square and Fisher’s exact
tests. Fisher’s exact test was used for SNP which has any cell size less than
10 observations in frequency table.
With respect to the risk of HF, an association was observed
among the African-American group for rs5051 when compar-
ing chlorthalidone to amlodipine, rs2493129 when comparing
chlorthalidone to lisinopril, and rs2493129 when comparing
lisinopril to amlodipine with OR = 1.6, OR = 0.6, and OR =
2.0, respectively. A suggestive gene by treatment interaction was
also observed among the Caucasian group at the rs2493129 locus
with OR = 0.5 (p = 0.02) when comparing chlorthalidone to
amlodipine. However, none of the tested models demonstrated
statistical significance after the Bonferroni correction for multiple
testing.
DISCUSSION
In this study, we evaluated whether AGT variants interact with
antihypertensive treatments to effect the risk of CHD and HF
during follow-up in GenHAT. Due to its high prevalence, the
annual healthcare costs of hypertension are sharply on the rise
(Heidenreich et al., 2011). Personalized antihypertensive treat-
ment may benefit patients by maximizing blood pressure control
andmitigating CVDmorbidity andmortality resulting in reduced
health care costs. Our results demonstrate that variation in the
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FIGURE 3 | Linkage disequilibrium structure of the seven studied AGT SNPs by race-specific group. The SNPs are shown sequentially as they appear on
the chromosome (not to scale). D’, coefficient of linkage disequilibrium; r, regression coefficient of linkage disequilibrium.
AGT gene might have a role in CHD and HF among hypertensive
patients.
Other groups have considered the association between AGT
polymorphisms and blood pressure response to antihypertensive
agents. For instance, Frazier et al. (2004) found that the A allele
of AGT G6A (rs5051) has a significant effect on systolic blood
pressure reduction in response to 25mg of hydrochlorothiazide
(a thiazide diuretic) in African American women. Another study
in 1447 hypertensive Chinese patients demonstrated that patients
with the minor allele (A) of the AGT rs7079 SNP had a bet-
ter blood pressure response to ACE inhibitors (benazepril) when
compared to ACE users with the common allele (Su et al., 2007).
Another group recently reported no difference in blood pressure
response to hydrochlorothiazide associated with rs7079 (Huang
et al., 2011). In sum, these studies suggest that variations in the
AGT gene may have an influence on blood pressure response to
antihypertensive therapies.
Other reports have found associations between SNPs in AGT
and CVD events. For example, in a cohort study of 4097 hyper-
tensive patients, ACE-inhibitor users with the minor allele (T) of
M235T (rs699) had higher risk of having MI and stroke com-
pared to non-users with the common allele (Schelleman et al.,
2007). Another prospective study, the Thrombogenic Factor and
Coronary Events (THROMBO) study, failed to show a signifi-
cant association between M235T and recurrent coronary events
in ACE inhibitor users (Goldenberg et al., 2006). Though these
models are not directly comparable to our own, they support
a role for the AGT gene in CVD risk during antihypertensive
treatment.
Suggestive findings for rs11122576 (associated with a greater
than two-fold risk of CHD) for two different treatment com-
parisons were observed in African Americans. Although these
findings did not meet our significance criteria, they provide
insight into genetic underpinnings of variation in response and
outcomes. The pharmacogenetic effect of rs11122576 comparing
chlorthalidone to amlodipine was in the opposite direction for
Caucasians (OR = 0.6, p = 0.01). This may be due to differences
in LD patterns in African Americans compared to Caucasians,
but suggests the SNP could be tagging some important variant
in both races. A recent study found a significant association of
the minor allele of rs11122576 with CHDmortality in a cohort of
1186 CHD participants mostly of European ancestry-after 3-years
of follow-up. The minor allele of rs1122576 was also associated
with of higher risk of renal disease, type 2 diabetes, and higher
body mass index in that study (Ellis et al., 2013). Similarly to the
CHD results, there were more marginally significant associations
among African Americans compared to Caucasians for the HF
outcome, however none were close to statistical significance.
The GenHAT study is a large, ethnically diverse sample ancil-
lary to a large clinical trial which facilitates pharmacogenetic
studies among well-defined treatment groups with extensive
adjudication of CVD outcomes. Despite this strength, our study
also has some limitations. First, ALLHAT recruited hyperten-
sive patients aged 55 years and older with a large proportion
of diabetes mellitus (36.0%) and/or evidence of atherosclerotic
cardiovascular disease (46.9%). Therefore, it may not be valid
to generalize the findings of this study to healthier and younger
populations. Second, the case-only design did not allow the evalu-
ation of the main effects of treatment or genotype on the outcome
(Khoury and Flanders, 1996). Third, we only had sufficient geno-
typed data for seven AGT SNPs, so this study cannot completely
evaluate the antihypertensive pharmacogenetic effects of the AGT
gene. Finally, and most importantly, we recognize most genomic
findings are greatly strengthened by replication studies. However,
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Table 3A | Genotype-by-treatment interaction results for genetic model (additive and dominant) among Caucasians.
Out-come AGT variant Number of cases (col %) ORs and p-values for genetic model, Caucasians
CHL AML LIS CHL vs. AML CHL vs. LIS LIS vs. AML
CHD (n = 1500) rs7079 CC 293 (43.9%) 191 (47.6%) 163 (44.2%) p = 0.13;
OR = 1.2;
CI(0.96–1.4)
p = 0.62; OR
= 1.0;
CI(0.9–1.3)
p = 0.36;
OR = 1.1;
CI(0.9–1.4)
AC 289 (43.3%) 170 (42.4%) 166 (45.0%)
AA 85 (12.7%) 40 (10.0%) 40 (10.8%)
rs5051 TT 135 (19.9%) 75 (18.7%) 65 (17.1%) p = 0.26;
OR = 1.1;
CI(0.9–1.3)
p = 0.49; OR
= 0.9;
CI(0.8–1.1)
p = 0.10;
OR = 1.2;
CI(1.0–1.4)
TC 296 (43.7%) 205 (51.1%) 175 (46.1%)
CC 247 (36.4%) 121 (30.2%) 140 (36.8%)
rs3789678 CC 542 (79.7%) 315 (78.0%) 312 (80.6%) p = 0.50;
OR = 0.9;
CI(0.7–1.2)
p = 0.72; OR
= 1.0;
CI(0.8–1.4)
p = 0.36;
OR = 0.9;
CI(0.6–1.2)
TC&CC 138 (20.3%) 89 (22%) 75 (19.4%)
rs2493133 CC 136 (20.4%) 76 (19.0%) 63 (16.9%) p = 0.43;
OR = 1.1;
CI(0.9–1.3)
p = 0.28; OR
= 0.9;
CI(0.8–1.1)
p = 0.09;
OR = 1.2;
CI(1.0–1.5)
TC 291 (43.6%) 201 (50.1%) 170 (45.6%)
TT 240 (36.0%) 124 (30.9%) 140 (37.5%)
rs2493129 GG 652 (95.2%) 378 (92.2%) 363 (93.3%) p = 0.04;
OR = 0.6;
CI(0.4–1.0)
p = 0.20; OR
= 0.7;
CI(0.4–1.2)
p = 0.54;
OR = 0.8;
CI(0.5–1.4)
AG&AA 33 (4.8%) 32 (7.8%) 26 (6.7%)
rs2478544 GG 452 (69.1%) 258 (68.1%) 254 (68.7%) p = 0.73;
OR = 1.0;
CI(0.7–1.3)
p = 0.88; OR
= 1.0;
CI(0.7–1.3)
p = 0.87;
OR = 1.0;
CI(0.7–1.3)
GC&CC 202 (30.9%) 121 (31.9%) 116 (31.3%)
rs11122576 AA 603 (88.7%) 342 (83.4%) 328 (84.1%) p = 0.01;
OR = 0.6;
CI(0.5–0.9)
p = 0.03; OR
= 0.7;
CI(0.5–1.0)
p = 0.79;
OR = 1.0;
CI(0.7–1.4)
AG&GG 77 (11.3%) 68 (16.6%) 62 (15.9%)
HF (n = 1094) rs7079 CC 208 (47.8%) 160 (48.0%) 121 (43.8%) p = 0.90;
OR = 1.0;
CI(0.8–1.2)
p = 0.98; OR
= 1.0;
CI(0.8–1.3)
p = 0.92;
OR = 1.0;
CI(0.8–1.3)
AC 173 (40.0%) 133 (40.0%) 132 (47.8%)
AA 54 (12.4%) 40 (12.0%) 23 (8.3%)
rs5051 TT 90 (20.4%) 68 (20.0%) 56 (19.5%) p = 0.50;
OR = 1.1;
CI(0.9–1.3)
p = 0.84; OR
= 1.0;
CI(0.8–1.3)
p = 0.67;
OR = 1.0;
CI(0.8–1.3)
TC 197 (44.6%) 166 (48.8%) 136 (47.4%)
CC 155 (35.1%) 106 (31.2%) 95 (33.1%)
rs3789678 CC 351 (78.9%) 266 (77.8%) 222 (78.7%) p = 0.71;
OR = 0.9;
CI(0.7–1.3)
p = 0.96; OR
= 1.0;
CI(0.7–1.4)
p = 0.78;
OR = 0.9;
CI(0.6–1.4)
TC&TT 94 (21.1%) 76 (22.3%) 60 (21.3%)
rs2493133 CC 87 (20.0%) 64 (18.9%) 56 (19.8%) p = 0.56;
OR = 1.1;
CI(0.9–1.3)
p = 0.55; OR
= 1.1;
CI(0.9–1.3)
p = 0.96;
OR = 1.0;
CI(0.8–1.2)
TC 192 (44.0%) 166 (49.1%) 135 (47.7%)
TT 157 (36.0%) 108 (32.0%) 92 (32.5%)
rs2493129 GG 429 (95.6%) 314 (91.3%) 269 (92.4%) p = 0.02;
OR = 0.5;
CI(0.3–0.9)
p = 0.08; OR
= 0.6;
CI(0.3–1.1)
p = 0.60;
OR = 0.9;
CI(0.5–1.5)
AG&AA 20 (4.4%) 30 (8.7%) 22 (7.6%)
rs2478544 GG 284(67.6%) 212 (64.1%) 187 (68%) p = 0.31;
OR = 0.9;
CI(0.6–1.2)
p = 0.92; OR
= 1.0;
CI(0.7–1.4)
p = 0.31;
OR = 0.8;
CI(0.6–1.2)
GC&CC 136 (32.4%) 119 (35.9%) 88 (32.1%)
rs11122576 AA 384 (85.9%) 295 (85.3%) 241 (83.1%) p = 0.80;
OR = 0.9;
CI(0.6–1.4)
p = 0.30; OR
= 0.8;
CI(0.5–1.2)
p = 0.46;
OR = 1.2;
CI(0.8–1.8)
AG&GG 63 (14.1%) 51 (14.8%) 49 (16.9%)
CHL, chlorthalidone; AML, amlodipine; LIS, lisinopril; CHD, coronary heart disease; HF, heart failure.
Dominant model was used for SNP which has any cell size less than 10 observations by collapsing minor allele homozygotes with heterozygotes which was
compared to common allele homozygotes. Additive model coded common homozygotes as 0, heterozygotes as 1; rare homozygotes as 2; and assumed linearity
(1-degree of freedom test).
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Table 3B | Genotype-by-treatment interaction results for genetic model (additive and dominant) among African Americans.
Out-come AGT variant Number of cases (col %) ORs and p-values for genetic model,
African Americans
CHL AML LIS CHL vs. AML CHL vs. LIS LIS vs. AML
CHD (n = 753) rs7079 CC 259 (78.3%) 175 (87.1%) 175 (85.0%) p = 0.01;
OR = 1.9;
CI(1.1–3.0)
p = 0.06;
OR = 1.6; CI
(1.0–2.5)
p = 0.54;
OR = 1.2;
CI(0.7–2.1)
AC&AA 72 (21.7%) 26 (12.9%) 31 (15%)
rs5051 TT 237 (71.6%) 150 (73.2%) 162 (78.3%) p = 0.69;
OR = 1.1;
CI(0.7–1.6)
p = 0.09;
OR = 1.4;
CI(1.0–2.1)
p = 0.23;
OR = 0.8;
CI(0.5–1.2)
TC&CC 94 (28.4%) 55 (26.8%) 45 (21.7%)
rs3789678 CC 215 (64.6%) 139 (69.9%) 126 (60.9%) p = 0.21;
OR = 1.3;
CI(0.9–1.9)
p = 0.39;
OR = 0.9;
CI(0.6–1.2)
p = 0.06;
OR = 1.5;
CI(1.0–2.2)
TC&TT 118 (35.4%) 60 (30.1%) 81 (39.1%)
rs2493133 CC 211 (64.5%) 134 (68.7%) 145 (71.1%) p = 0.33;
OR = 1.2;
CI(0.8–1.8)
p = 0.12;
OR = 1.4;
CI(0.9–2.0)
p = 0.61;
OR = 0.9;
CI(0.6–1.4)
TC&TT 116 (35.5%) 61 (31.3%) 59 (28.9%)
rs2493129 GG 288 (86.0%) 164 (82.4%) 180 (86.5%) p = 0.27;
OR = 0.8;
CI(0.5–1.2)
p = 0.85;
OR = 1.0;
CI(0.6–1.7)
p = 0.25;
OR = 0.7;
CI(0.4–1.3)
AG&AA 47 (14%) 35 (17.6%) 28 (13.5%)
rs2478544 GG 96 (31.3%) 48 (25.7%) 63 (32.1%) p = 0.31;
OR = 0.9;
CI(0.7–1.1)
p = 0.97;
OR = 1.0;
CI(0.8–1.3)
p = 0.34;
OR = 0.9;
CI(0.7–1.2)
GC 144 (47.0%) 96 (51.3%) 89 (45.4%)
CC 67 (21.8%) 43 (23.0%) 44 (22.5%)
rs11122576 AA 294 (87.5%) 191 (94.6%) 181 (87.0%) p = 0.006;
OR = 2.5;
CI(1.2–4.9)
p = 0.87;
OR = 1.0;
CI(0.6–1.6)
p = 0.01;
OR = 2.6;
CI(1.2–5.4)
AG&GG 42 (12.5%) 11 (5.5%) 27 (13%)
HF (n = 634) rs7079 CC 190 (80.9%) 181 (86.2%) 154 (86.0%) p = 0.13;
OR = 1.5;
CI(0.9–2.5)
p = 0.16;
OR = 1.5;
CI(0.9–2.5)
p = 0.96;
OR = 1.0;
CI(0.6–1.8)
AC&AA 45 (19.1%) 29 (13.9%) 25 (14%)
rs5051 TT 157 (67.1%) 160 (76.2%) 125 (69.8%) p = 0.03;
OR = 1.6;
CI(1.0–2.4)
p = 0.55;
OR = 1.1;
CI(0.7–1.7)
p = 0.16;
OR = 1.4;
CI(0.9–2.2)
TC&CC 77 (32.9%) 50 (23.8%) 54 (30.2%)
rs3789678 CC 147(62.8%) 124 (60.5%) 100 (55.9%) p = 0.59;
OR = 0.9;
CI(0.7–1.3)
p = 0.16;
OR = 0.8;
CI(0.6–1.1)
p = 0.38;
OR = 1.2;
CI(0.8–1.6)
TC 76 (32.5%) 70 (34.2%) 68 (38.0%)
TT 11 (4.7%) 11 (5.4%) 11 (6.2%)
rs2493133 CC 145 (62.5%) 142 (69.3%) 117 (66.5%) p = 0.14;
OR = 1.4;
CI(0.9–2.0)
p = 0.41;
OR = 1.2;
CI(0.8–1.8)
p = 0.56;
OR = 1.1;
CI(0.7–1.8)
TC&TT 87 (37.5%) 63 (30.7%) 59 (33.5%)
rs2493129 GG 207 (87.7%) 189 (89.2%) 143 (80.3%) p = 0.64;
OR = 1.2;
CI(0.6–2.1)
p = 0.04;
OR = 0.6;
CI(0.3–1.0)
p = 0.02;
OR = 2.0;
CI(1.1–3.6)
AG&AA 29 (12.3%) 23 (10.9%) 35 (19.7%)
rs2478544 GG 72 (32.6%) 56 (28.4%) 63 (38.7%) p = 0.56;
OR = 0.9;
CI(0.7–1.2)
p = 0.35;
OR = 1.1;
CI(0.9–1.5)
p = 0.14;
OR = 0.8;
CI(0.6–1.1)
GC 105 (47.5%) 102 (51.8%) 69 (42.3%)
CC 44 (20.0%) 39 (19.8%) 31 (19.0%)
rs11122576 AA 214 (91.1%) 196 (92.9%) 161 (89.0%) p = 0.48;
OR = 1.3;
CI(0.6–2.6)
p = 0.47;
OR = 0.8;
CI(0.4–1.5)
p = 0.18;
OR = 1.6;
CI(0.8–3.3)
AG&GG 21 (8.9%) 15 (7.2%) 20 (11%)
CHL, chlorthalidone; AML, amlodipine; LIS, lisinopril; CHD, coronary heart disease; HF, heart failure.
Dominant model was used for SNP which has any cell size less than 10 observations by collapsing minor allele homozygotes with heterozygotes which was
compared to common allele homozygotes. Additive model coded common homozygotes as 0, heterozygotes as 1; rare homozygotes as 2; and assumed linearity
(1-degree of freedom test).
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due to specific drug regimens and SNP selections in GenHAT
comparable study populations are difficult to find.
The findings reported here for antihypertensive treatment
effects of seven AGT SNPs in 2253 CHD cases and 1728 HF cases
suggest that a patient’s AGT variants might help predict which
hypertensive medication(s) can lower cardiovascular disease risk.
Our results highlight rs11122576 for African American partici-
pants where the minor allele of rs11122576 was associated with
over two-fold higher risk of CHD for chlorthalidone treatment
compared to amlodipine treatment and lisinopril treatment com-
pared to amlodipine treatment (p = 0.006 and p = 0.01, respec-
tively). Although marginally significant, our results demonstrate
biological relevance in a large, racially diverse population. These
findings need to be investigated further and confirmed in inde-
pendent sample of hypertensive patients.
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